ANN ARBOR, MI -- (Marketwire) -- 11/26/12 -- TSRL, Inc. is a privately-owned specialty pharmaceutical company focused on the discovery and development of orally available antiviral and anticancer therapeutics based on its proprietary prodrug technology.
The company announced today that it entered into a collaborative research and development agreement (CRADA) with the Walter Reed Army Institute of Research. TSRL's proprietary drug candidates, TSR-087 and TSR-505, have demonstrated significant broad-spectrum antiviral activity in non-clinical studies. The purpose of this Agreement is to conduct additional in vitro studies to further evaluate the activity of these compounds against contemporary, clinically important adenovirus strains.
TSR-087 and TSR-505 have been developed to date through SBIR funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).